Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

Documenti analoghi

• Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
  di: Dekkers, Claire C J, et al.
  Pubblicazione: (2018)
• Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
  di: Dekkers, Claire C. J., et al.
  Pubblicazione: (2019)
• Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers
  di: Idzerda, Nienke M A, et al.
  Pubblicazione: (2019)
• Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baseline
  di: Stefánsson, Bergur V., et al.
  Pubblicazione: (2021)
• Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
  di: Fioretto, Paola, et al.
  Pubblicazione: (2016)